Photo taken from Iván González/X
Dec 23, 2023, 03:51
Iván González: Interesting review that addresses the importance of the RAS/RAF/MAPK pathway in solid cancers
Iván González, Medical Oncologist at the Ángeles Puebla Hospital, shared a post on X/Twitter:
“A very interesting review that addresses the importance of the RAS/RAF/MAPK pathway in solid cancers, focusing on resistance to RAF inhibitors (RAFi). It highlights the RAF-MEK-ERK signaling cascade and its role in tumorigenesis, underlining that mutations in this pathway are associated with cancer.
- Although RAFi and MEK blockers have demonstrated efficacy in cancers with RAF mutations, resistance to therapy remains a concern.
- It is suggested that combining RAF inhibitors with agents that modulate autophagy could overcome resistance.
- In addition, pharmacological approaches, such as hydroxychloroquine, are mentioned and the efficacy of therapeutic combinations, such as Dabrafenib, Trametinib and hydroxychloroquine in BRAFV600 mutant melanoma is highlighted.
- The review argues for future research exploring autophagy inhibitors and emerging technologies, such as AUTOTAC. Also noteworthy is the evaluation of safety when combining BRAF and MEK inhibitors with helper peptides, cancer vaccines, and research into combination therapies with other compounds.”
For details, click here.
Source: Iván González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19